::: MAX BioPharma ::: https://maxbiopharma.com/ Molecules For Advanced Therapeutics Wed, 11 Mar 2026 22:42:06 +0000 en-US hourly 1 https://maxbiopharma.com/wp-content/uploads/favicon.bmp ::: MAX BioPharma ::: https://maxbiopharma.com/ 32 32 MAX BioPharma and Technomark Life Sciences Announce Investment and Partnership Agreement in Developing Oxysterol-Based Drug Candidate for MASH https://maxbiopharma.com/max-biopharma-and-technomark-life-sciences-announce-investment-and-partnership-agreement-in-developing-oxysterol-based-drug-candidate-for-mash Wed, 11 Mar 2026 22:39:17 +0000 https://maxbiopharma.com/?p=242314
MAX BioPharma and Technomark Life Sciences Partnership

MAX BioPharma and Technomark Life Sciences announced their collaboration in the development of MAX BioPharma’s oxysterol drug candidate, Oxy210, targeting metabolic dysfunction-associated steatohepatitis (MASH). As a strategic lead investor, Technomark is participating in MAX BioPharma’s $13 million Series A raise to initiate and complete a Phase 1a/1b first-in-human study and is inviting aligned investors from the industry to join this opportunity.

Read the full press release >

]]> MAX BioPharma and Revilico Announce Collaboration on Target Identification and Mechanistic Studies for Oxysterol Drug Candidates https://maxbiopharma.com/max-biopharma-and-revilico-announce-collaboration-on-target-identification-and-mechanistic-studies-for-oxysterol-drug-candidates Thu, 07 Aug 2025 00:12:16 +0000 https://maxbiopharma.com/?p=242283

MAX BioPharma, Inc. and Revilico, Inc. announced their collaboration in studying the mechanisms of action, performing lead optimization, and identifying the molecular targets of MAX BioPharma’s oxysterol-based drug candidates using a state-of-the-art, AI-enabled, end-to-end drug discovery platform developed by Revilico.

View the original press release >

]]> Oxy210 Reduces Senescence and Fibrosis in MASH Models https://maxbiopharma.com/oxy210-reduces-senescence-and-fibrosis-in-mash-models Sun, 03 Aug 2025 23:52:44 +0000 https://maxbiopharma.com/?p=242287

MAX BioPharma Reports on Oxy210’s Inhibition of Hepatic Expression of Senescence-Associated, Pro-Fibrotic, and Pro-Inflammatory Genes in Mice During Development of MASH and in Hepatocytes In Vitro.

Read the full study >

]]> Oxy210 Inhibits Atherosclerosis in Preclinical Models https://maxbiopharma.com/oxy210-inhibits-atherosclerosis-in-preclinical-models Fri, 13 Jun 2025 22:30:36 +0000 https://maxbiopharma.com/?p=242210 MAX BioPharma reports on the Inhibition of Atherosclerosis in Hyperlipidemic Mice and Inflammatory Responses of Vascular Cells by its Oxysterol Drug Candidate, Oxy210

Paper available from https://pubmed.ncbi.nlm.nih.gov/39404395/

]]> Metaba and MAX BioPharma Announce Breakthrough Progress on Next-Generation Oxysterol-Based Antibiotics https://maxbiopharma.com/metaba-and-max-biopharma-announce-breakthrough-progress-on-next-generation-oxysterol-based-antibiotics Fri, 21 Feb 2025 02:30:10 +0000 https://maxbiopharma.com/?p=242097

https://www.prnewswire.com/news-releases/metaba-and-max-biopharma-announce-breakthrough-progress-on-next-generation-oxysterol-based-antibiotics-302379559.html?tc=eml_cleartime

]]> MAX BioPharma Will Be Attending the Biocom Global Partnering & Investor Conference https://maxbiopharma.com/max-biopharma-will-be-attending-the-biocom-global-partnering-investor-conference-2 Fri, 14 Feb 2025 02:23:38 +0000 https://maxbiopharma.com/?p=242098

MAX BioPharma in collaboration with Metaba will be presenting at Biocom California’s 15th Annual Global Life Science Partnering & Investor Conference scheduled for February 25th – February 28th in La Jolla, California.

]]> MAX Pharma Inc. Announces Collaboration with Metaba, LLC to Study Metabolomics as They Develop Novel Oxysterol Drug Candidates https://maxbiopharma.com/max-pharma-inc-announces-collaboration-with-metaba-llc-to-study-metabolomics-as-they-develop-novel-oxysterol-drug-candidates Tue, 27 Feb 2024 02:30:42 +0000 https://maxbiopharma.com/?p=242046 MAX BioPharma and Metaba Announce Collaboration on Metabolomics Studies : https://www.prnewswire.com/news-releases/max-biopharma-and-metaba-announce-collaboration-on-metabolomics-studies-302070283.html

]]> MAX BioPharma Will Be Attending the Biocom Global Partnering & Investor Conference https://maxbiopharma.com/max-biopharma-will-be-attending-the-biocom-global-partnering-investor-conference Tue, 27 Feb 2024 02:29:25 +0000 https://maxbiopharma.com/?p=242041

MAX BioPharma will be attending Biocom’s Global Life Science Partnering & Investor conference scheduled for February 27th – February 29th in La Jolla, California. The Company’s Founder, President & CEO, Farhad Parhami, will present the latest news on its pipeline and current fundraising efforts on Wednesday February 28th.

]]> MAX BioPharma to Attend Biocom’s Global Life Science Partnering & Investor Conference https://maxbiopharma.com/max-biopharma-to-attend-biocoms-global-life-science-partnering-investor-conference Fri, 03 Feb 2023 01:27:57 +0000 http://mbf.local/?p=2356

MAX BioPharma will be attending Biocom’s Global Life Science Partnering & Investor conference scheduled for February 28th – March 2nd. The Company’s Founder & CEO, Farhad Parhami, is scheduled to present the latest news on its pipeline and current fundraising efforts on March 1st. 

]]> Inhibition of Profibrotic Signaling by Oxy210 https://maxbiopharma.com/inhibition-of-profibrotic-signaling-oxy210 Fri, 03 Feb 2023 01:19:43 +0000 http://mbf.local/?p=2352 MAX BioPharma reports on the inhibition of profibrotic signaling in cellular models of lung and kidney fibrosis by its oxysterol drug candidate, Oxy210, an orally available small molecule.

 

Please follow the link for a copy of the manuscript. https://www.mdpi.com/1424-8247/16/1/114

]]>